AU2577799A - 45 human secreted proteins - Google Patents

45 human secreted proteins

Info

Publication number
AU2577799A
AU2577799A AU25777/99A AU2577799A AU2577799A AU 2577799 A AU2577799 A AU 2577799A AU 25777/99 A AU25777/99 A AU 25777/99A AU 2577799 A AU2577799 A AU 2577799A AU 2577799 A AU2577799 A AU 2577799A
Authority
AU
Australia
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25777/99A
Other languages
English (en)
Inventor
Hla Kyaw
David W. Lafleur
Paul A Moore
Craig A Rosen
Steven M. Ruben
Yanggu Shi
Ying-Fei Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2577799A publication Critical patent/AU2577799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
AU25777/99A 1998-02-09 1999-02-04 45 human secreted proteins Abandoned AU2577799A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US7411898P 1998-02-09 1998-02-09
US7434198P 1998-02-09 1998-02-09
US7403798P 1998-02-09 1998-02-09
US7415798P 1998-02-09 1998-02-09
US7414198P 1998-02-09 1998-02-09
US60074341 1998-02-09
US60074157 1998-02-09
US60074118 1998-02-09
US60074141 1998-02-09
US60074037 1998-02-09
PCT/US1999/002293 WO1999040100A1 (en) 1998-02-09 1999-02-04 45 human secreted proteins

Publications (1)

Publication Number Publication Date
AU2577799A true AU2577799A (en) 1999-08-23

Family

ID=27535993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25777/99A Abandoned AU2577799A (en) 1998-02-09 1999-02-04 45 human secreted proteins

Country Status (6)

Country Link
US (8) US6569992B1 (enExample)
EP (1) EP1053245A4 (enExample)
JP (1) JP2002502589A (enExample)
AU (1) AU2577799A (enExample)
CA (1) CA2320625A1 (enExample)
WO (1) WO1999040100A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
ATE402954T1 (de) * 1998-03-20 2008-08-15 Genentech Inc Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
WO1999055733A1 (en) * 1998-04-24 1999-11-04 Smithkline Beecham Corporation Cloning of a novel 7tm receptor axor-2
US6951921B2 (en) * 1998-09-01 2005-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1135492A1 (en) * 1998-11-25 2001-09-26 Millennium Pharmaceuticals, Inc. 12216 receptor, a g-protein coupled receptor
US7026449B2 (en) * 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
DE60031418T2 (de) 1999-08-03 2007-08-23 Millennium Pharmaceuticals, Inc., Cambridge 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
JP2003514520A (ja) * 1999-11-05 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２９個のヒト分泌タンパク質
CA2390438A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 19 human secreted proteins
CA2390421A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
AU2001247283A1 (en) * 2000-03-06 2001-09-17 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
JP2004528006A (ja) * 2000-09-29 2004-09-16 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
WO2002092804A1 (en) * 2001-05-15 2002-11-21 Biovitrum Ab Metalloprotease m8 polynucleotides and polypeptides and screening methods
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
ES2577532T3 (es) * 2002-10-25 2016-07-15 Genentech, Inc. Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
US20040248257A1 (en) * 2003-04-30 2004-12-09 The Scripps Research Institute SPEX compositions and methods of use
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
TWI472535B (zh) 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP3141560A3 (en) 2008-05-06 2017-05-24 Genentech, Inc. Affinity matured crig variants
US8957075B2 (en) 2009-06-01 2015-02-17 President And Fellows Of Harvard College O-GlcNAc transferase inhibitors and uses thereof
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN112980883B (zh) * 2021-03-03 2022-04-12 广州达博生物制品有限公司 一种人γ-干扰素病毒载体及其应用
AU2022288080A1 (en) * 2021-06-11 2023-12-07 Monsanto Technology Llc Methods and compositions for altering protein accumulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5118617A (en) * 1989-05-19 1992-06-02 Applied Research Systems Ars Holding N.V. Saf polypeptide, gene coding therefor, saf promoter and expression methods for expressing foreign dna sequences in streptomyces
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5744355A (en) * 1994-10-18 1998-04-28 Mayo Foundation For Medical Education And Research cDNA cloning and expression of human liver estrogen sulfotransferase
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20060223088A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
JP2001518793A (ja) * 1997-04-10 2001-10-16 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
US20030073129A1 (en) * 1998-09-01 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002502605A (ja) 1998-02-09 2002-01-29 ジェンセット 分泌タンパク質をコードするｃＤＮＡ
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
CA2479498A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
EP1396543A3 (en) 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
EP1242443A4 (en) 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
EP1274715A2 (en) 2000-04-06 2003-01-15 Genetics Institute, Inc. Polynucleotides encoding novel secreted proteins
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
EP1053245A1 (en) 2000-11-22
US20060281095A1 (en) 2006-12-14
US6569992B1 (en) 2003-05-27
WO1999040100A1 (en) 1999-08-12
US20030096982A1 (en) 2003-05-22
US20050079537A1 (en) 2005-04-14
CA2320625A1 (en) 1999-08-12
US20070154918A1 (en) 2007-07-05
US20050009085A1 (en) 2005-01-13
JP2002502589A (ja) 2002-01-29
US20050153335A1 (en) 2005-07-14
US6924356B2 (en) 2005-08-02
EP1053245A4 (en) 2002-04-17
US20090088555A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
AU4682999A (en) 94 human secreted proteins
AU5134799A (en) 98 human secreted proteins
AU2577799A (en) 45 human secreted proteins
AU5583799A (en) 49 human secreted proteins
AU6552198A (en) 28 human secreted proteins
AU2306499A (en) 110 human secreted proteins
AU7099200A (en) 52 human secreted proteins
AU3124000A (en) 47 human secreted proteins
AU6952998A (en) 20 human secreted proteins
AU2471899A (en) 67 human secreted proteins
AU1438001A (en) 27 human secreted proteins
AU2451199A (en) 36 human secreted proteins
AU8066998A (en) 86 human secreted proteins
AU1448701A (en) 15 human secreted proteins
AU9130498A (en) 50 human secreted proteins
AU5212299A (en) 71 human secreted proteins
AU5928899A (en) 31 human secreted proteins
AU1334101A (en) 19 human secreted proteins
AU1231400A (en) 12 human secreted proteins
AU8404598A (en) 64 human secreted proteins
AU3006799A (en) 31 human secreted proteins
AU1273499A (en) 148 human secreted proteins
AU8921598A (en) 29 human secreted proteins
AU1342501A (en) 32 human secreted proteins
AU4018100A (en) 49 human secreted proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase